Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 5;196(17):E601-E607.
doi: 10.1503/cmaj.230356-f.

Percées dans la prise en charge de l’hypernéphrome

[Article in French]
Luisa M Cardenas  1 , Samantha Sigurdson  1 , Christopher J D Wallis  1 , Aly-Khan Lalani  2 , Anand Swaminath  2
Affiliations
Review

Percées dans la prise en charge de l’hypernéphrome

[Article in French]
Luisa M Cardenas et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Intérêts concurrents:: Christopher Wallis a reçu des honoraires de services conseils des sociétés Janssen Oncology, Nanostics Inc., Precision Point Specialty LLC, Sesen Bio; des honoraires ou des frais de voyage des sociétés AbbVie, Astellas, AstraZeneca, Bayer, EMD Serono, Haymarket Media, Janssen, Knight Therapeutics, Merck, Science & Medicine Canada, TerSera Canada, Tolmar Pharmaceuticals Canada et de la Fondation Healing and Cancer Foundation; du financement de recherche de la part des sociétés Knight Therapeutics, Tolmar Pharmaceuticals et Bayer. Aly-Khan Lalani a reçu des honoraires ou des frais de service conseil des sociétés AbbVie, Astellas Pharma, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Janssen, Merck, Novartis, Pfizer, Roche/Genentech et TerSera, et du financement de recherche des sociétés Bristol Myers Squibb, BioCanRx, EMD Serono, Ipsen, Novartis et Roche. Anand Swaminath a reçu des honoraires des sociétés Bristol Myers Squibb, Eisai, et AstraZeneca, et occupe un poste à titre bénévole au sein du conseil consultatif médical de l’Association canadienne du cancer du rein.

References

    1. Brenner DR, Poirier A, Woods RR, et al. . Projected estimates of cancer in Canada in 2022. CMAJ 2022;194:E601–7. - PMC - PubMed
    1. Bukavina L, Bensalah K, Bray F, et al. . Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82:529–42. - PubMed
    1. Wah TM, Irving HC, Gregory W, et al. . Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014;113:416–28. - PMC - PubMed
    1. Motzer RJ, McDermott DF, Escudier B, et al. . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022;128:2085–97. - PMC - PubMed
    1. Richard PO, Violette PD, Bhindi B, et al. . Canadian Urological Association guideline: Management of small renal masses: full text. Can Urol Assoc J 2022; 16: E61–75. - PMC - PubMed

LinkOut - more resources